Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib study of DFF332 alone and in combination in advanced ccRCC and HIF2α-mutant malignancies
jRCT2031210239Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of DFF332 in clear cell renal cell carcinoma (ccRCC), von Hippel–Lindau disease (VHL), hereditary leiomyomatosis and renal cell cancer (HLRCC) and 2 more (7 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Tolerability (dose modifications and intensity) and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
DFF332
03
Conditions
clear cell renal cell carcinoma (ccRCC)von Hippel–Lindau disease (VHL)hereditary leiomyomatosis and renal cell cancer (HLRCC)Hereditary Pheochromocytoma-Paraganglioma Syndrome (PGL/PCC)cancer
Beyond the preview
Go deeper on jRCT2031210239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210239.